Stocks › EBS

Emergent BioSolutions Inc.

EBS·NYSE·United States United States·USD
$5.05
-0.10 (-1.94%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
EBS
Emergent BioSolutions Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
EBSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of EBS by members of U.S. Congress · 13 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Steve CohenSteve CohenHouse · D · TN EBSEmergent BioSolutions Inc. · Stock Sale
$1,001 - $15,000
Jan 10, 2025 Dec 11, 2024 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ EBSEmergent BioSolutions Inc. · Stock Sale
$1,001 - $15,000
Dec 13, 2021 Nov 5, 2021 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ EBSEmergent BioSolutions Inc. · Stock Purchase
$1,001 - $15,000
Nov 15, 2021 Oct 18, 2021 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ EBSEmergent BioSolutions Inc. · Stock Sale
$1,001 - $15,000
Oct 13, 2021 Sep 15, 2021 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ EBSEmergent BioSolutions Inc. · Stock Sale
$1,001 - $15,000
Mar 10, 2021 Feb 23, 2021 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA EBSEmergent BioSolutions Inc. · Stock Purchase
$1,001 - $15,000
Dec 15, 2020 Nov 24, 2020 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA EBSEmergent BioSolutions Inc. · Stock Purchase
$1,001 - $15,000
Aug 19, 2020 Jul 30, 2020 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA EBSEmergent BioSolutions Inc. · Stock Purchase
$1,001 - $15,000
Jul 17, 2020 Jun 30, 2020 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA EBSEmergent BioSolutions Inc. · Stock Purchase
$1,001 - $15,000
Jul 17, 2020 Jun 19, 2020 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ EBSEmergent BioSolutions Inc. · Stock Purchase
$1,001 - $15,000
Jul 9, 2020 Jun 15, 2020 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ EBSEmergent BioSolutions Inc. · Stock Purchase
$1,001 - $15,000
Jul 9, 2020 Jun 26, 2020 Filing ↗
Steve CohenSteve CohenHouse · D · TN EBSEmergent BioSolutions Inc. · Stock Sale
$1,001 - $15,000
Apr 22, 2020 Mar 26, 2020 Filing ↗
Steve CohenSteve CohenHouse · D · TN EBSEmergent BioSolutions Inc. · Stock Sale
$15,001 - $50,000
Sep 12, 2019 Aug 29, 2019 Filing ↗

Whale Activity

Position changes in EBS reported for 2026-09-30 by 223 institutional filers
Increased: 69New: 31Held: 26Decreased: 55Closed: 37No prior filing: 5
  • Increased69
  • New31
  • Held26
  • Decreased55
  • Closed37
  • No prior filing5
FilerSharesValueChange
BlackRock, Inc.5.2M$34.1Mincreased
AMERICAN CENTURY COMPANIES INC3.3M$21.9Mincreased
STATE STREET CORP2.7M$17.9Mdecreased
DIMENSIONAL FUND ADVISORS LP2.6M$16.9Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC2.2M$14.3Mdecreased
LSV ASSET MANAGEMENT2.0M$13.1M—
ACADIAN ASSET MANAGEMENT LLC1.9M$12.8Mincreased
MILLENNIUM MANAGEMENT LLC1.9M$12.4Mincreased
OAK HILL ADVISORS LP1.5M$10.0Mincreased
GEODE CAPITAL MANAGEMENT, LLC1.3M$8.4Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC1.2M$7.8Mincreased
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.1.1M$7.5Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by EBS insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: -45.0K2025 Q12025 Q2: 52.2K2025 Q22025 Q3: -14.9K2025 Q32025 Q4: -78.9K2025 Q42026 Q1: 02026 Q12026 Q2: -65.9K2026 Q22026 Q3: -3,0002026 Q32026 Q4: -20.8K2026 Q4

Recent Insider Transactions

2,962 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
DeGolyer Donald WDirector · Director Sale −17.8K $7.09 $126K Oct 7, 2026 Form 4 ↗
Williams Paul AnthonySVP, Products Business Sale −3,000 $6.53 $20K Oct 1, 2026 Form 4 ↗
Williams Paul AnthonySVP, Products Business Sale −3,000 $8.40 $25K Jul 1, 2026 Form 4 ↗
Hartzel WilliamSVP, Bioservices Tax withholding −1,741 $8.00 $14K Jun 8, 2026 Form 4 ↗
Williams Paul AnthonySVP, Products Business Tax withholding −694 $8.00 $6K Jun 8, 2026 Form 4 ↗
Glessner ColeenEVP, Quality & Ethics, and CPL Tax withholding −2,018 $8.00 $16K Jun 8, 2026 Form 4 ↗
LINDAHL RICHARD SEVP, Chief Financial Officer Tax withholding −3,964 $8.00 $32K Jun 8, 2026 Form 4 ↗
Zoon Kathryn CDirector Sale −1,057 $8.97 $9K May 1, 2026 Form 4 ↗
Zoon Kathryn CDirector Sale −16.1K $8.36 $135K May 1, 2026 Form 4 ↗
DeGolyer Donald WDirector Sale −954 $8.96 $9K May 1, 2026 Form 4 ↗
DeGolyer Donald WDirector Sale −14.5K $8.36 $121K May 1, 2026 Form 4 ↗
Dayal Sujata TyagiDirector Sale −980 $8.94 $9K May 1, 2026 Form 4 ↗
Dayal Sujata TyagiDirector Sale −12.8K $8.36 $107K May 1, 2026 Form 4 ↗
Zoon Kathryn CDirector Grant / award +25.3K $0.00 $0 Apr 30, 2026 Form 4 ↗
DeGolyer Donald WDirector Grant / award +25.3K $0.00 $0 Apr 30, 2026 Form 4 ↗
Dayal Sujata TyagiDirector Grant / award +25.3K $0.00 $0 Apr 30, 2026 Form 4 ↗
Fowler Neal FranklinDirector Grant / award +25.3K $0.00 $0 Apr 30, 2026 Form 4 ↗
White Marvin LDirector Grant / award +25.3K $0.00 $0 Apr 30, 2026 Form 4 ↗
Harsanyi ZsoltChairman · Director Grant / award +25.3K $0.00 $0 Apr 30, 2026 Form 4 ↗
Richard RonaldDirector Grant / award +25.3K $0.00 $0 Apr 30, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding EBS · SEC Form N-PORT
FundSharesValue% of fundAs of
Avantis U.S. Small Cap Value ETF
American Century ETF Trust
2.8M$17.0M0.05%Aug 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
1.7M$14.3M0.13%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.6M$13.0M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
1.4M$11.6M0.01%Jun 30, 2026
U.S. SMALL CAP VALUE PORTFOLIO
DFA INVESTMENT DIMENSIONS GROUP INC
705.6K$5.1M0.03%Jul 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
592.8K$5.0M0.01%Jun 30, 2026
Federated Hermes MDT Small Cap Core Fund
Federated Hermes MDT Series
630.3K$4.6M0.20%Jul 31, 2026
VANGUARD STRATEGIC EQUITY FUND
VANGUARD HORIZON FUNDS
528.6K$4.4M0.04%Jun 30, 2026
iShares Russell 2000 Value ETF
iShares Trust
502.4K$4.2M0.03%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
569.1K$4.1M0.01%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list EBS's shares (CUSIP 29089Q105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Oak Hill Advisors LPSCHEDULE 13G/A · passive (13G) · 4.0M shares7.5%
    Nov 16, 2026 · ↗
  • Stowers Institute for Medical ResearchSCHEDULE 13G/A · passive (13G) · 3.3M shares6.5%
    Nov 16, 2026 · ↗
  • American Century Companies, Inc.SCHEDULE 13G/A · passive (13G) · 3.3M shares6.5%
    Nov 16, 2026 · ↗
  • American Century Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 3.3M shares6.5%
    Nov 16, 2026 · ↗
  • American Century ETF TrustSCHEDULE 13G/A · passive (13G) · 3.2M shares6.2%
    Nov 16, 2026 · ↗
  • Vanguard Capital ManagementSCHEDULE 13G/A · passive (13G) · 2.5M shares4.9%
    Jul 31, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 4.7M shares9.0%
    Jul 28, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming emergent biosolutions as client
$0$1.3M$2.5M$3.8M$5.0M2023 Q1: $1.3M2023 Q2: $1.2M2023 Q3: $895K2023 Q4: $875K20232024 Q1: $1.1M2024 Q2: $835K2024 Q3: $835K2024 Q4: $920K20242025 Q1: $1.1M2025 Q2: $630K2025 Q3: $720K2025 Q4: $620K20252026 Q1: $890K2026 Q2: $670K2026 Q3: $585K2026
  • CGCN GROUP, LLCEMERGENT BIOSOLUTIONS INC. · 2026 Q3 · BUD, DIS, HCR, HOM$60K
    Filing ↗
  • THE NICKLES GROUP, LLCEMERGENT BIOSOLUTIONS · 2026 Q3 · BUD, HCR, DEF$25K
    Filing ↗
  • CAPITOL COUNSEL LLCEMERGENT BIOSOLUTIONS · 2026 Q3 · HCR$50K
    Filing ↗
  • EMERGENT BIOSOLUTIONS INC.EMERGENT BIOSOLUTIONS INC · 2026 Q3 · HOM, DIS, BUD, HCR$450K
    Filing ↗
  • CGCN GROUP, LLCEMERGENT BIOSOLUTIONS INC. · 2026 Q2 · DIS, HCR, HOM, BUD$70K
    Filing ↗

Government Contracts

Federal awards to emergent biosolutions · USAspending
$320.9MAwarded · 1 contract on record
  • Department of Health and Human ServicesBOTULISM ANTITOXIN$320.9M
    Sep 30, 2019 · ↗

U.S. Patents

Recent USPTO applications naming Emergent BioSolutions Inc.

No USPTO patent applications found for Emergent BioSolutions Inc..

Annual Financials

From EBS's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$742.9M$1.04B$1.05B$1.12B$1.77B
Operating income$100.1M-$108.7M-$726.4M-$170.0M$341.4M
Net income$52.6M-$190.6M-$760.5M-$211.6M$219.5M
Diluted EPS$0.93-$3.60-$14.85-$4.22$4.06
Operating cash flow$170.6M$58.7M-$206.3M-$34.1M$320.2M
Cash and equivalents$205.4M$99.5M$111.7M$642.6M$576.1M
Total assets$1.32B$1.39B$1.82B$3.17B$2.96B
Total liabilities$796.0M$906.9M$1.17B$1.78B$1.34B
Shareholders' equity$522.6M$482.8M$649.3M$1.39B$1.61B

As Emergent BioSolutions Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 27, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in EBS's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 8.01, 9.01Other eventsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureNov 2, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeOct 16, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureSep 14, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 1, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 2.05, 5.02, 7.01, 9.01Results of operations · Exit or disposal costs · Officer / director changeAug 5, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureJun 29, 2026
    EDGAR ↗

About Emergent BioSolutions Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersGAITHERSBURG, MD
IncorporatedDE